Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
6.29
-0.23 (-3.53%)
At close: May 13, 2025, 4:00 PM
6.30
+0.01 (0.16%)
Pre-market: May 14, 2025, 6:20 AM EDT
Arvinas Revenue
Arvinas had revenue of $188.80M in the quarter ending March 31, 2025, with 646.25% growth. This brings the company's revenue in the last twelve months to $426.90M, up 498.74% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$426.90M
Revenue Growth
+498.74%
P/S Ratio
1.06
Revenue / Employee
$992,791
Employees
430
Market Cap
459.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ARVN News
- 21 hours ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation - Accesswire
- 2 days ago - Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect - Accesswire
- 5 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - Accesswire